{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:41:43Z","timestamp":1761932503112,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.aprim.2025.103354","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:03:37Z","timestamp":1757369017000},"page":"103354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efectividad de los agonistas del receptor GLP-1 en el manejo de pacientes diab\u00e9ticos tipo 2"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-4193","authenticated-orcid":false,"given":"Ferran","family":"Bejarano Romero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Arag\u00f3 Mol\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mor\u00f3n Porr\u00faa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"L\u00f3pez Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Su\u00f1er Barriga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Canadell Vilarrasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aprim.2025.103354_bib0150","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.pcd.2022.10.005","article-title":"Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world","volume":"16","author":"Franch-Nadal","year":"2022","journal-title":"Primary Care Diabetes."},{"key":"10.1016\/j.aprim.2025.103354_bib0155","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care."},{"key":"10.1016\/j.aprim.2025.103354_bib0160","doi-asserted-by":"crossref","first-page":"19351","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis","volume":"9","author":"Castellana","year":"2019","journal-title":"Sci Rep."},{"key":"10.1016\/j.aprim.2025.103354_bib0165","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/672658","article-title":"Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis","volume":"2012","author":"Monami","year":"2012","journal-title":"Exp Diabetes Res."},{"key":"10.1016\/j.aprim.2025.103354_bib0170","unstructured":"Victoza\u00ae. Ficha t\u00e9cnica. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/09529002\/."},{"key":"10.1016\/j.aprim.2025.103354_bib0175","unstructured":"Trulicity\u00ae. Ficha t\u00e9cnica. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/114956002\/."},{"key":"10.1016\/j.aprim.2025.103354_bib0180","unstructured":"Ozempic\u00ae. Ficha t\u00e9cnica. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/117251002\/."},{"key":"10.1016\/j.aprim.2025.103354_bib0185","unstructured":"Rybelsus\u00ae. Ficha t\u00e9cnica. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/p\/1201430002\/."},{"key":"10.1016\/j.aprim.2025.103354_bib0190","unstructured":"Bydureon\u00ae. Ficha t\u00e9cnica. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/111696003\/."},{"key":"10.1016\/j.aprim.2025.103354_bib0195","unstructured":"Lyxumia\u00ae. Ficha t\u00e9cnica. Disponible en: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/12811003\/."},{"key":"10.1016\/j.aprim.2025.103354_bib0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pcd.2021.11.006","article-title":"Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies","volume":"16","author":"Xu","year":"2022","journal-title":"Primary Care Diabetes."},{"key":"10.1016\/j.aprim.2025.103354_bib0205","unstructured":"BIFIMED [consultado 8 May 2025]. Disponible en https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=723346"},{"key":"10.1016\/j.aprim.2025.103354_bib0210","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2025.103354_bib0215","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2025.103354_bib0220","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25mg and 50mg compared with 14mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2025.103354_bib0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.aprim.2025.103354_bib0230","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2025.103354_bib0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.aprim.2025.103354_bib0240","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med."},{"year":"2025","series-title":"Overweight and obesity management (NG246).","key":"10.1016\/j.aprim.2025.103354_bib0245"},{"issue":"Suppl. 1","key":"10.1016\/j.aprim.2025.103354_bib0250","first-page":"S128","article-title":"Glycemic goals and hypoglycemia: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care."},{"key":"10.1016\/j.aprim.2025.103354_bib0255","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.aprim.2025.103354_bib0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez","year":"2013","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.aprim.2025.103354_bib0265","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ."},{"key":"10.1016\/j.aprim.2025.103354_bib0270","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40618-022-01799-2","article-title":"Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients","volume":"45","author":"Marzullo","year":"2022","journal-title":"J Endocrinol Invest."},{"key":"10.1016\/j.aprim.2025.103354_bib0275","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2012.04.013","article-title":"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review","volume":"34","author":"Aroda","year":"2012","journal-title":"Clin Ther."},{"key":"10.1016\/j.aprim.2025.103354_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104996","article-title":"Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes","volume":"159","author":"Berra","year":"2020","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.aprim.2025.103354_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111928","article-title":"Real world effectiveness of semaglutide: Focus on patients with type 2 diabetes older than 75 years","volume":"218","author":"Baronti","year":"2024","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.aprim.2025.103354_bib0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med."}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656725001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656725001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:28:46Z","timestamp":1761931726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656725001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0212656725001404"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2025.103354","relation":{},"ISSN":["0212-6567"],"issn-type":[{"type":"print","value":"0212-6567"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectividad de los agonistas del receptor GLP-1 en el manejo de pacientes diab\u00e9ticos tipo 2","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2025.103354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103354"}}